Tevogen (TVGN) Bio Holdings announced it has received the previously reported $1M in funding to advance Tevogen.AI. The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in nondilutive funding. KRHP LLC is affiliated with an existing Tevogen investor. Following Tevogen.AI’s recent announcement of the patent publication of its proprietary machine learning technology for predicting immunologically active peptides, the Company plans to use the funding to accelerate Tevogen.AI’s capabilities, enhancing target discovery, shortening development timelines, and improving treatment accessibility for large patient populations.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen expanding collaboration with Microsoft and Databricks
- Tevogen signs letter of intent for new cell therapy manufacturing facility
- AI Daily: OpenAI said to end acquisition talks with Windsurf
- Tevogen.AI builds alpha version of PredicTcell model
- Tevogen Bio Grants Restricted Stock to CEO